Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 7,762 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: High Grade Clear all
Completed Not applicable Interventional Results available

Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression

NCT05693922
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation, Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC
Device · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 21, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Results available

Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme

NCT00837824
View directory record Official record
Conditions
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Interventions
Fabrazyme (agalsidase beta)
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
9
States / cities
Farmington, Connecticut • Coral Springs, Florida • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Early Phase 1 Interventional

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

NCT03099980
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 21, 2026, 4:50 AM EDT
Active, not recruiting Phase 3 Interventional

ABTECT - Maintenance

NCT05535946
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABX464, Placebo
Drug
Lead sponsor
Abivax S.A.
Industry
Eligibility
16 Years and older
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
72
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Sun City, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery

NCT00266786
View directory record Official record
Conditions
Postoperative Pain
Interventions
Intranasal Ketorolac Tromethamine, Intranasal Placebo
Drug
Lead sponsor
Egalet Ltd
Industry
Eligibility
18 Years to 64 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
Arcadia, California • Glendale, California • Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

NCT05203341
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, NBI-1065845
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Huntsville, Alabama • Riverside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 21, 2026, 4:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

NCT03597594
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
Anti-thymocyte globulin (rabbit), Busulfan, Fludarabine, Thiotepa, CliniMACS, Donor Lymphocyte Infusion
Drug · Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Months and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 4:50 AM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

NCT06636656
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BI 3032950 intravenous (Part A), BI 3032950 subcutaneous (Part B)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
14
States / cities
Scottsdale, Arizona • Colorado Springs, Colorado • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency

NCT01347931
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
Interventions
NIOV System, Standard Oxygen Cannula
Device
Lead sponsor
Breathe Technologies, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 21, 2026, 4:50 AM EDT
Withdrawn Phase 1 Interventional

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

NCT04594031
View directory record Official record
Conditions
Sickle Cell Disease, Umbilical Cord Blood, Hematopoietic Cell Proliferation
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
5 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Palo Alto, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Octreotide in Severe Polycystic Liver Disease

NCT00426153
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions
Octreotide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 21, 2026, 4:50 AM EDT
Terminated Not applicable Interventional

RESIPI for Reducing Perioperative Major Adverse Cardiac Events

NCT03208023
View directory record Official record
Conditions
Inotropy, Fluid Management, Cardiac Event, Perioperative Cardiac Risk, Vascular Resistance, Hemodynamic Monitoring, Hemodynamic Management, Fluid Responsiveness
Interventions
RESIPI Management Strategy, No intervention
Procedure · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effects of Duloxetine on Norepinephrine

NCT00414323
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Escitalopram, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Glendale, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Oct 21, 2026, 4:50 AM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

NCT06055361
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BxC-I17e (primed iMSC derived Extracellular vesicles(EV)), Placebo
Drug
Lead sponsor
Brexogen Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
North Little Rock, Arkansas • Camp Hill, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Not applicable Interventional

Study of an Electronic Health Record-embedded Severe Sepsis Early Warning Alert

NCT02376842
View directory record Official record
Conditions
Severe Sepsis
Interventions
Severe sepsis early warning best practice alert, Standard care
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 21, 2026, 4:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examination of Glutamate and mGluR5 in Psychiatric Disorders

NCT02727972
View directory record Official record
Conditions
Major Depressive Disorder, Post-Traumatic Stress Disorder, Bipolar Disorder
Interventions
Cognitive Testing, MRI, PET
Behavioral · Other · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03010527
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • West Des Moines, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Tralokinumab in Adults With Asthma

NCT01402986
View directory record Official record
Conditions
Asthma
Interventions
Placebo Q2W, Tralokinumab 300 mg, Q2W, Placebo, Q2/4W, Tralokinumab 300 mg, Q2/4W
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
11
States / cities
Rancho Mirage, California • Centennial, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

NCT05919069
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AZD2693
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rialto, California • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Not applicable Interventional

Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma

NCT01018329
View directory record Official record
Conditions
Brain Tumor
Interventions
Magnetic Resonance Imaging, Diffusion Tensor Imaging, Magnetic Resonance Spectroscopic Imaging, Dynamic Contract-Enhanced magnetic resonance imaging, Diffusion-weighted magnetic resonance imaging
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 21, 2026, 4:50 AM EDT
Recruiting Phase 2 Interventional

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

NCT07116031
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Belumosudil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 4:50 AM EDT
Terminated Phase 1 Interventional

Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease

NCT00278577
View directory record Official record
Conditions
CROHN'S DISEASE
Interventions
Immune Ablation and Hematopoietic Stem Cell Support
Biological
Lead sponsor
Richard Burt, MD
Other
Eligibility
Up to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

NCT03675477
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 21, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 21, 2026, 4:50 AM EDT